@article{nuijten_incorporation_2005,
	title = {Incorporation of uncertainty in health economic modelling studies.},
	volume = {23},
	issn = {1170-7690},
	abstract = {In a recent leading article in PharmacoEconomics, Nuijten described some Abstract methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are found to suffer from serious flaws in statistical and health economic reasoning. Nuijten's suggestions for incorporating uncertainty: (a) wrongly interpret the p-value as the probability that the null hypothesis is true; (b) represent this probability wrongly by truncating the input distribution; and (c) in the specific example of an antiparkinsonian drug uses a completely inappropriate p-value of 0.05 when the null hypothesis would, in reality, be emphatically disproved by the data. His suggestions regarding minimum important differences in cost effective-ness: (a) introduce areas of indifference that suggest inappropriate reliance on cost minimisation while failing to recognise that decisions should be based on expected costs versus benefits; and (b) offer no guidance on how the probabilities associated with these areas could be used in decision-making. Furthermore, Nuijten's model for Parkinson's disease is over-simplified to the point of provid-ing a bad example of modelling practice, which may mislead the readers of PharmacoEconomics. The rationale for this paper is to ensure that readers do not apply inappropriate analyses as a result of following the proposals contained in Nuijten's paper. In addition to a detailed critique of Nuijten's proposals, we provide brief summaries of the currently accepted best practice in cost-effectiveness decision-making under uncertainty.},
	number = {8},
	journal = {PharmacoEconomics},
	author = {Nuijten, Mark},
	year = {2005},
	pmid = {16097845},
	pages = {851--3; author reply 853},
}

{"_id":"C8sHyTnRDehMhewDm","bibbaseid":"nuijten-incorporationofuncertaintyinhealtheconomicmodellingstudies-2005","author_short":["Nuijten, M."],"bibdata":{"bibtype":"article","type":"article","title":"Incorporation of uncertainty in health economic modelling studies.","volume":"23","issn":"1170-7690","abstract":"In a recent leading article in PharmacoEconomics, Nuijten described some Abstract methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are found to suffer from serious flaws in statistical and health economic reasoning. Nuijten's suggestions for incorporating uncertainty: (a) wrongly interpret the p-value as the probability that the null hypothesis is true; (b) represent this probability wrongly by truncating the input distribution; and (c) in the specific example of an antiparkinsonian drug uses a completely inappropriate p-value of 0.05 when the null hypothesis would, in reality, be emphatically disproved by the data. His suggestions regarding minimum important differences in cost effective-ness: (a) introduce areas of indifference that suggest inappropriate reliance on cost minimisation while failing to recognise that decisions should be based on expected costs versus benefits; and (b) offer no guidance on how the probabilities associated with these areas could be used in decision-making. Furthermore, Nuijten's model for Parkinson's disease is over-simplified to the point of provid-ing a bad example of modelling practice, which may mislead the readers of PharmacoEconomics. The rationale for this paper is to ensure that readers do not apply inappropriate analyses as a result of following the proposals contained in Nuijten's paper. In addition to a detailed critique of Nuijten's proposals, we provide brief summaries of the currently accepted best practice in cost-effectiveness decision-making under uncertainty.","number":"8","journal":"PharmacoEconomics","author":[{"propositions":[],"lastnames":["Nuijten"],"firstnames":["Mark"],"suffixes":[]}],"year":"2005","pmid":"16097845","pages":"851–3; author reply 853","bibtex":"@article{nuijten_incorporation_2005,\n\ttitle = {Incorporation of uncertainty in health economic modelling studies.},\n\tvolume = {23},\n\tissn = {1170-7690},\n\tabstract = {In a recent leading article in PharmacoEconomics, Nuijten described some Abstract methods for incorporating uncertainty into health economic models and for utilising the information on uncertainty regarding the cost effectiveness of a therapy in resource allocation decision-making. His proposals are found to suffer from serious flaws in statistical and health economic reasoning. Nuijten's suggestions for incorporating uncertainty: (a) wrongly interpret the p-value as the probability that the null hypothesis is true; (b) represent this probability wrongly by truncating the input distribution; and (c) in the specific example of an antiparkinsonian drug uses a completely inappropriate p-value of 0.05 when the null hypothesis would, in reality, be emphatically disproved by the data. His suggestions regarding minimum important differences in cost effective-ness: (a) introduce areas of indifference that suggest inappropriate reliance on cost minimisation while failing to recognise that decisions should be based on expected costs versus benefits; and (b) offer no guidance on how the probabilities associated with these areas could be used in decision-making. Furthermore, Nuijten's model for Parkinson's disease is over-simplified to the point of provid-ing a bad example of modelling practice, which may mislead the readers of PharmacoEconomics. The rationale for this paper is to ensure that readers do not apply inappropriate analyses as a result of following the proposals contained in Nuijten's paper. In addition to a detailed critique of Nuijten's proposals, we provide brief summaries of the currently accepted best practice in cost-effectiveness decision-making under uncertainty.},\n\tnumber = {8},\n\tjournal = {PharmacoEconomics},\n\tauthor = {Nuijten, Mark},\n\tyear = {2005},\n\tpmid = {16097845},\n\tpages = {851--3; author reply 853},\n}\n\n","author_short":["Nuijten, M."],"key":"nuijten_incorporation_2005","id":"nuijten_incorporation_2005","bibbaseid":"nuijten-incorporationofuncertaintyinhealtheconomicmodellingstudies-2005","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/davidrpoa","dataSources":["fvS7tt2THEKMbWDXR"],"keywords":[],"search_terms":["incorporation","uncertainty","health","economic","modelling","studies","nuijten"],"title":"Incorporation of uncertainty in health economic modelling studies.","year":2005}